- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07909590
A Study Evaluating the Impact of a Painkiller Product on Quality-of-Life and Daily Functioning
A Multi-country, Retrospective, Real World Observational Study Evaluating the Impact of an Analgesic Product on Quality-of-Life and Daily Functioning
The aim of this study is to generate real-world, consumer reported evidence on the perceived impact of headache relief with Panadol/Dolex on Quality of Life (QoL) and daily functioning.
연구 개요
상세 설명
This is a multi-country, real-world, observational, cross-sectional survey study. The target population for this survey study comprises individuals who have used Panadol/Dolex for the relief of more than or equal to (>=)1 headache episode in the past 1 month. Eligible participants will be directed to complete an online survey comprising of a series of questions designed to gather data relevant to the research objectives. The study population will be comprised of approximately 2,100 participants across Australia, Malaysia, Colombia, and Kenya.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Haleon Response Center
- 전화번호: +441932 95 95 00
- 이메일: ww.clinical-trial-register@haleon.com
연구 장소
-
-
Marina Centre
-
Singapore, Marina Centre, 싱가포르
- Virtual site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Residents of Australia, Malaysia, Colombia, Kenya who have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month and have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.
설명
Inclusion Criteria:
- Residents of Australia, Malaysia, Colombia, Kenya.
- Have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month.
- Have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.
- Self-reported healthy individuals.
- Able to provide informed consent.
- The specific Panadol/Dolex variant for each country as applicable.
Exclusion Criteria:
- Participants who experience headaches that occur 15 or more days per month.
- Participants with migraine.
- Participants who use any headache medication, pain relief product or alternative remedy (herbal products, supplements, CBD [cannabidiol]- containing pain remedies) concurrently with Panadol/Dolex for the recalled headache episode in the past 1 month.
- Participants diagnosed by a healthcare professional with chronic pain conditions (fibromyalgia, neuropathic pain, cancer, lupus, multiple sclerosis) who were experiencing symptoms or receiving treatment for the condition at the time of reference headache episode when Panadol/Dolex was used.
- Breastfeeding or Pregnant at the time of reference headache episode during which Panadol/Dolex was used.
- Participants affiliated with Sponsor or Contract Research Organization (CRO).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: CROSS_SECTIONAL
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Panadol/Dolex Tablet
Participants who have taken Panadol/Dolex for at least 1 headache episode in the past 1 month. |
Paracetamol 500 milligram (mg) taken orally. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pain Intensity Before Using Panadol/Dolex
기간: Within the past 1 month from time of participation
|
Thinking about most recent headache episode, participants will be asked to rate the pain intensity experienced before using Panadol/Dolex on a scale 0 to 10, where 0= No pain and 10= Worst possible pain. Lower score indicates better outcome. |
Within the past 1 month from time of participation
|
|
Perceived Relief From Panadol/Dolex Use
기간: Within the past 1 month from time of participation
|
Thinking about the headache episode, participants will describe the first sign of symptom relief they perceived after taking Panadol/Dolex. |
Within the past 1 month from time of participation
|
|
QoL Assessment After Using Panadol/Dolex Post Headache Episode
기간: Within the past 1 month from time of participation
|
Thinking about most recent headache episode, participants will be asked to respond to 10 questions related to aspects of daily life when they used Panadol/Dolex after headache episode. The response will be scored using a 5-point scale, where 1= Not at all, and 5= Very Much. Lower score indicates better quality of life. |
Within the past 1 month from time of participation
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Frequency of Panadol/Dolex Use
기간: Within the past 1 month from time of participation
|
Thinking about the recent headache episode, participants will be asked to mention the frequency of product use from 1 time a day to 4 times a day. |
Within the past 1 month from time of participation
|
|
Timepoint of Panadol/Dolex Use
기간: Within the past 1 month from time of participation
|
Participants will answer a single question related to timepoint of product use- 'Thinking about the same headache episode which you used Panadol for relief in the past one month, what did you first do to relieve the pain?' Participants will choose one of the given options. |
Within the past 1 month from time of participation
|
|
Product Satisfaction
기간: Within the past 1 month from time of participation
|
Thinking about the experience of using Panadol, participants will rate their overall satisfaction on a scale 1 to 5, where 1= Absolutely dissatisfied and 5= Completely satisfied. |
Within the past 1 month from time of participation
|
|
Headache Management Behaviors
기간: Within the past 1 month from time of participation
|
Participants will answer a single question related to headache management approaches they used before- 'Thinking about similar headaches you experienced before this episode, what did you do to relieve your headache in the past?' Participants will select one or more descriptive options provided. |
Within the past 1 month from time of participation
|
|
User Attitudes Towards Panadol/Dolex: Trust in The Product
기간: Within the past 1 month from time of participation
|
Participants will answer a single question related to trust in the product- 'How much do you trust the product to provide fast headache pain relief?' Participants will choose one of the given options. |
Within the past 1 month from time of participation
|
|
User Attitudes Towards Panadol/Dolex: Value For Money
기간: Within the past 1 month from time of participation
|
Thinking about experience of using the product, participants will be asked to rate the product's value for money on a scale 1 to 5, where 1= Poor value for money and 5= Excellent value for money. |
Within the past 1 month from time of participation
|
|
User Attitudes Towards Panadol/Dolex: Intention to Use Again
기간: Within the past 1 month from time of participation
|
Participants will answer a single question related to continued purchase- 'How likely would you choose Panadol again for your next headache episode?'. Participants will choose one of the given options. |
Within the past 1 month from time of participation
|
|
User Attitudes Towards Panadol/Dolex: Intention to Recommend Other Consumers
기간: Within the past 1 month from time of participation
|
Participants will answer a single question related to likelihood to recommend others- How likely would you recommend Panadol to other consumers experiencing headache pain? Participants will choose one of the given options. |
Within the past 1 month from time of participation
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 400384
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com
IPD 공유 기간
IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
IPD 공유 액세스 기준
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .